filmov
tv
MCRC
0:02:15
Dr. Overman Discusses ReDOS Study in mCRC
0:03:01
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC
0:01:43
Survival Differences in KRAS/BRAF Mutations in mCRC
0:06:11
Future Directions in Later Line Therapy for mCRC
0:02:18
Prognosticating BRAF-Mutant mCRC
0:03:51
Combining BRAF, MEK and EGFR Inhibition in mCRC
0:02:14
STELLAR-303: XL092 with atezolizumab compared to regorafenib in patients with mCRC
0:01:45
BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC
0:08:55
Exploring Second-Line Therapeutic Options in mCRC
0:04:57
Case 2: Maintenance Therapy in mCRC
0:05:02
The Rationale for FOLFOX and Bevacizumab in mCRC
0:01:00
Dr. Lenz on Next Steps With Immunotherapy in mCRC
0:04:53
Treatment strategy algorithm for mCRC
0:01:04
Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC
0:00:57
Analyzing the Importance of Biomarker Testing and MSI Status in mCRC
0:01:32
CodeBreak 300: patient-reported tolerability of sotorasib and panitumumab in mCRC
0:03:04
Treatment Goals in Refractory mCRC
0:01:11
32 month follow-up of MOUNTAINEER: tucatinib and trastuzumab in HER2+ mCRC
0:02:28
The evolving treatment paradigm for BRAF V600E-mutant mCRC
0:03:49
mCRC: Combination Therapy and Testing
0:01:46
Dr. Overman on Investigational Targeted Therapies in mCRC
0:01:11
CheckMate-8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
0:01:43
Areas of Controversy in the Treatment Landscape of mCRC
0:01:56
Biomarker-driven treatment strategies for mCRC in the CAPRI 2-GOIM trial
Назад
Вперёд
0:02:15
0:03:01
0:01:43
0:06:11
0:02:18
0:03:51
0:02:14
0:01:45
0:08:55
0:04:57
0:05:02
0:01:00
0:04:53
0:01:04
0:00:57
0:01:32
0:03:04
0:01:11
0:02:28
0:03:49
0:01:46
0:01:11
0:01:43
0:01:56